JLJoseph Levitt
Joseph Levitt
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph Levitt has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andrew D. Leavitt
Department of Laboratory Medicine, University of California, San Francisco, CA, USA
2 shared publications - Angela J. Rogers
Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, USA
2 shared publications - B Taylor Thompson
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, MA, USA
2 shared publications - Carolyn S. Calfee
UCSF, San Francisco, California, USA
2 shared publications - David H. McKenna
Molecular & Cellular Therapeutics, University of Minnesota, Saint Paul, Minnesota, USA
2 shared publications - Hanjing Zhuo
Cardiovascular Research Institute, University of California San Francisco, San Francisco, California
2 shared publications
Latest Publications
- Top Cited Papers
- 1 January 2015
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 3 (1) , 24-32
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
- 1 January 2015
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 3 (1) , 24-32
Top Cited PapersMesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
- Open Access
- 1 January 2014
- Published by Elsevier in Annals of Intensive Care
- Vol. 4 (1) , 1-9
Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome
- 1 January 2014
- Published by Elsevier in Annals of Intensive Care
- Vol. 4 (1) , 1-9
Open AccessDesign and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome